Logo

Ferrer, Oryzon to Co-Develop Genomic, Proteomic Tools for Colorectal Cancer

Apr 04, 2005

NEW YORK, April 4 (GenomeWeb News) - Ferrer International and Oryzon Genomics have formed a collaboration to develop new genomic- and proteomic-based products for the early diagnosis and prognosis of colorectal cancer, the firms said yesterday.

 

According to the Spanish companies, their partnership will include the genomic and proteomic analysis of hundreds of tumor samples in order to uncover clues about colorectal cancer and how to improve molecular tools for diagnosis and prognosis of the disease.

 

The initial research portion of the collaboration is expected to last two years, and will require an investment of almost €1 million, the companies said. The effort is being supported by the Catalan Institute of Oncology and the College Hospital Vall d'Hebron, they added.

Breaking News
The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.